Table 2. Immunization with recombinant vaccinia gp70 protects against CT26 tumor challenge.
Mice were immunized with either vaccinia gp70, vaccinia β-gal, or HBSS and challenged i.v. 3 weeks later with CT26 or CT26.CL25 (β-gal-transduced CT26) tumor. Lung metastases were counted 12 days later and the mean value calculated (SD in parentheses). CT26-challenged mice that received vaccinia gp70 developed significantly fewer metastases than vaccinia β-gal- or HBSS-treated mice. Both vaccinia β-gal and vaccinia gp70 were effective in preventing tumor development in mice challenged with CT26.CL25.